Breast cancer drug Kisqali outperformed its 2025 sales target by 9%, while a portfolio of recent launches that includes radioligand therapy Pluvicto, kidney disease drugs Fabhalta and Vanrafia, and ...

Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new ...

All together, the initiative is meant to help HCPs “better understand the full lived experience of ADHD, including its impact on school or work performance, relationships and self-esteem,” according ...

Large drugmakers once had more room to absorb failure, both financially and reputationally | Large drugmakers are facing tighter constraints than in the past, as financial, scientific and reputational ...

With online health and wellness company Hims & Hers opening a new front in the GLP-1 compounding showdown Thursday, the ...

After a brief delay last month, another piece of the Trump administration’s healthcare policy has fallen into place. | ...

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has ...

During the first six months of Maziar Mike Doustdar's tenure as Novo Nordisk's CEO, the company enjoyed a run of positive ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter ...

Amid the fast-moving rollout of the Wegovy pill, Novo Nordisk has taken to advertising’s biggest stage to help get the word ...

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...